| MSD-INTERNATIONAL-BUSINESS-GMBH |
MSD-INTERNATIONAL-BUSINESS-GMBH |
85%
|
Pursuant to the MSD Agreement, we provide ficerafusp alfa and MSD provides pembrolizumab to be used in combination in a clinical trial sponsored by us. |
| MSD-INTERNATIONAL-GMBH |
MSD-INTERNATIONAL-GMBH |
85%
|
Pursuant to the MSD Agreement, we provide ficerafusp alfa and MSD provides pembrolizumab to be used in combination in a clinical trial sponsored by us. |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from BCAX graph: inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assuranc… |
| AZN |
AstraZeneca PLC |
72%
|
inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. A… |
| BNTX |
BioNTech SE |
72%
|
Reciprocal relationship from BNTX graph: Reciprocal relationship from BCAX graph: inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assuran… |
| BNTX |
BioNTech SE |
72%
|
inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. A… |
| GNMSF |
Genmab A/S |
72%
|
inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. A… |
| GNMSF |
Genmab A/S |
72%
|
Reciprocal relationship from GNMSF graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from GNMS… |
| GSK |
GSK plc |
72%
|
inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. A… |
| GSK |
GSK plc |
72%
|
Reciprocal relationship from GSK graph: Reciprocal relationship from BCAX graph: inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assuranc… |
| INBX |
Inhibrx Biosciences, Inc. |
72%
|
Reciprocal relationship from INBX graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from INBX graph: Reciprocal relationship from BCAX graph: inancial institutions where we main… |
| INBX |
Inhibrx Biosciences, Inc. |
72%
|
inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. A… |
| JNJ |
Johnson & Johnson |
72%
|
inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. A… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from BCAX graph: inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assuranc… |
| MS-PE |
Morgan Stanley |
72%
|
Reciprocal relationship from MS-PE graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from MS-PE graph: Reciprocal relationship from BCAX graph: inue to incur significant financi… |
| MS-PK |
Morgan Stanley |
72%
|
inue to incur significant financial losses for the foreseeable future. We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in December 2018, and our ope… |
| PLRX |
Pliant Therapeutics, Inc. |
72%
|
Reciprocal relationship from PLRX graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX g… |
| PYXS |
Pyxis Oncology, Inc. |
72%
|
inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. A… |
| PYXS |
Pyxis Oncology, Inc. |
72%
|
Reciprocal relationship from PYXS graph: Reciprocal relationship from BCAX graph: inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assuran… |
| AKESO-INC-ASTRAZENECA-PLC-AVEO-PHARMACEUTICALS-I |
AKESO-INC-ASTRAZENECA-PLC-AVEO-PHARMACEUTICALS-I |
62%
|
inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. A… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
ed to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate significant revenue from sales of our product candidate, if ever, we expect to finance … |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
ur products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination; the manufacturing facilities in which our product… |
| HONG-KONG-LIMITED |
HONG-KONG-LIMITED |
62%
|
ur suppliers, many of which are located outside of the United States, are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of ope… |
| USA-LLC |
USA-LLC |
62%
|
nse and other 1,219 1,119 100 Total general and administrative expenses $ 12,742 $ 7,455 $ 5,287 The increase in general and administrative expenses for the three months ended March 31, 2026, compare… |
